Imagine a world where the constant fear of a life-threatening diabetes complication could be significantly reduced. A groundbreaking paper, spearheaded by Breakthrough T1D, offers a potential solution: the first international consensus guidance for continuous ketone monitoring (CKM). This could be a game-changer for individuals at risk of diabetic ketoacidosis (DKA).
Breakthrough T1D, the world's leading organization dedicated to type 1 diabetes (T1D) research and advocacy, recently announced the publication of this pivotal paper in The Lancet Diabetes & Endocrinology. The paper, titled "Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology," isn't just another research article; it's a blueprint. You can find the full text here: (https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00331-6/fulltext). This framework provides standardized recommendations for the effective use of CKM, paving the way for its integration into routine diabetes care.
The paper was meticulously crafted by a distinguished international team of diabetes experts. Leading the charge were Thomas Danne, M.D., Chief Medical Officer at Breakthrough T1D; Dr. Ketan Dhatariya, a Consultant in Diabetes and Endocrinology at Norfolk and Norwich University Hospitals and Honorary Professor of Medicine at the University of East Anglia; and Dr. Richard Bergenstal, Executive Director of the International Diabetes Center, HealthPartners Institute. Their combined expertise ensures that the guidelines are both scientifically sound and practically applicable for healthcare professionals and the entire T1D community.
So, what's the big deal about ketones? Individuals with diabetes are susceptible to DKA, a serious and potentially fatal condition. DKA occurs when the body, lacking sufficient insulin, starts breaking down stored fat for energy. This process releases ketones into the bloodstream, causing it to become dangerously acidic. Think of it like this: your body is forced to use an alternative fuel source, but this fuel produces harmful byproducts. DKA can strike unexpectedly, often triggered by illnesses like the flu. While traditional methods like blood and urine ketone strips exist, they have limitations. They offer only a snapshot in time, making it difficult to anticipate rapidly rising ketone levels. And this is the part most people miss... the predictive element. Continuous monitoring offers a proactive approach.
This is where CKM comes into play. Much like continuous glucose monitors (CGMs) revolutionized blood sugar management, CKMs continuously measure ketone levels in the body. They provide real-time data and, crucially, alert users to rising ketone levels. This early warning system empowers individuals to take timely action, potentially preventing DKA altogether and enabling safer, more effective insulin therapy. Imagine the peace of mind knowing you have a constant guardian against this dangerous complication.
According to Breakthrough T1D Chief Medical Officer Thomas Danne, M.D., "Continuous ketone monitoring has the potential to be a transformational new technology and tool for those living with diabetes and at risk of the life-threatening complication, diabetic ketoacidosis." He emphasizes the critical role of these new guidelines in preparing the diabetes community to effectively utilize CKM technology once it becomes widely available, ultimately leading to improved health outcomes. "Breakthrough T1D is grateful to all who were on the consensus panel who provided their expertise and came together to develop practical and actionable recommendations that will advance the field and improve diabetes care for all who face the condition."
Breakthrough T1D's commitment to accelerating the adoption of CKM is evident in their leadership. They convened a panel of 33 international experts from 14 countries to develop this comprehensive consensus guidance. The recommendations address key aspects of CKM use, including standardized terminology for describing ketone levels, visual device elements for displaying ketone changes, alarm thresholds and triggers, and essential ketone education. This initiative perfectly aligns with Breakthrough T1D's mission to accelerate the clinical adoption of innovative treatments and therapies for T1D. But here's where it gets controversial... what about the cost and accessibility of this technology? Will it be available to everyone who needs it, or will it exacerbate existing health disparities?
About Breakthrough T1D (formerly JDRF)
Breakthrough T1D is the leading global type 1 diabetes research and advocacy organization. Their mission is to improve the lives of people with T1D today and accelerate the search for a cure. They achieve this by investing in cutting-edge research, advocating for policies that benefit the T1D community, and providing education and support to individuals and families affected by the condition.
About Type 1 Diabetes (T1D)
T1D is an autoimmune disease in which the body's immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. This results in little to no insulin production, requiring individuals with T1D to rely on insulin therapy for survival. T1D can lead to a range of short- and long-term complications, including fluctuations in blood sugar levels, damage to vital organs, and even death. It affects approximately 9.5 million people worldwide. Contrary to popular belief, T1D can be diagnosed at any age, with nearly 50% of diagnoses occurring in adulthood. The onset of T1D is not related to diet or lifestyle choices. While the exact causes remain unknown, scientists believe that a combination of genetic predisposition and environmental triggers plays a role. Currently, there is no cure for T1D.
What are your thoughts on continuous ketone monitoring? Do you think it will truly revolutionize diabetes care, or are there potential drawbacks we need to consider? Share your opinions in the comments below!
Contact:
Casey Fielder
509-651-0087
email protected
SOURCE Breakthrough T1D, Formerly JDRF
